Fresenius Medical Care AG (ETR:FME – Get Free Report)’s share price passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of €40.39 ($42.52) and traded as high as €45.35 ($47.74). Fresenius Medical Care shares last traded at €44.68 ($47.03), with a volume of 247,059 shares traded.
Fresenius Medical Care Trading Down 1.7 %
The company has a current ratio of 1.37, a quick ratio of 0.80 and a debt-to-equity ratio of 82.24. The company has a 50-day simple moving average of €45.20 and a 200 day simple moving average of €40.39. The firm has a market cap of $12.98 billion, a PE ratio of 19.70, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
- Five stocks we like better than Fresenius Medical Care
- What Are Dividends? Buy the Best Dividend Stocks
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Read Stock Charts for Beginners
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- What is a Low P/E Ratio and What Does it Tell Investors?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.